Sector News

Bayer offloads Dr. Scholl’s foot care brand for $585M as major revamp presses on

July 23, 2019
Life sciences

Bayer’s healthcare shake-up just took another big step forward. After selling its Coppertone sun care line, the company has worked up a deal for the Dr. Scholl’s foot care brand.

Private equity firm Yellow Wood Partners agreed to buy Bayer’s Dr. Scholl’s business for $585 million. The products brought in €198 million ($234 million) last year, ranking ninth among Bayer’s consumer health brands.

The deal marks the second planned sale in Bayer’s over-the-counter department as part of a bigger shake-up unveiled in November. Bayer penned a pact in May to sell Coppertone to Nivea maker Beiersdorf for $550 million.

Boston-based Yellow Wood, exclusively focused in the consumer industry, will create a standalone Dr. Scholl’s company with the current Bayer employees. The private investment shop’s portfolio includes Freeman Beauty, which also markets foot care products.

Bayer’s entire consumer franchise has been under pressure lately. In 2018, its sales in the sector dropped 6.3%, mainly on lackluster performance in the U.S. as competition intensifies.

Now that Coppertone and Dr. Scholl’s are off the to-do list, Bayer’s next big hive-off is its animal health unit. The company reportedly approached Eli Lilly’s animal health spinoff Elanco about a potential tie-up, but Elanco may not have enough cash to buy Bayer’s division.

All these sell-offs, along with a cost-saving plan and a layoff round, are part of Bayer’s cash-raising efforts in the wake of its $63 billion Monsanto buy. Bayer plans to channel the freed-up resources into strengthening its pharma business, mainly via external collaborations.

The Monsanto deal—and management’s approach to the mounting Roundup litigation that came along with it—have drawn much criticism from shareholders. Last week, a federal judge rejected Bayer’s request for a retrial in one case, but did slash the damages Bayer owed to $25.27 million from $80.27 million.

Given that Bayer has lost its Roundup lawsuits one after another, Bernstein analysts have argued for the company to consider settling. In a move that suggests a deal may indeed be on the horizon, Bayer hired an independent lawyer to advise it on the Roundup suits, and it set up a special committee to oversee the effort.

By Angus Liu

Source: Fierce Pharma

comments closed

Related News

February 25, 2024

Pharma CFOs need R&D vigilance in tough economic times

Life sciences

As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.

February 25, 2024

Agilent CEO Mike McMullen to retire, succeeded by lab services head

Life sciences

McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.

February 25, 2024

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

Life sciences

AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.

How can we help you?

We're easy to reach